ArticleTranslational gastroenterology and hepatology2026
ORM2 protects against acute pancreatitis by inhibiting premature activation of pancreatic enzymes.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pancreatitis (AP) is characterized by dysregulated pancreatic enzyme activation and pancreatic tissue injury. Orosomucoid (ORM), an acute-phase protein with immunomodulatory functions, exhibits organ-specific expression patterns, but its role in AP remains unclear. This study investigated the isoform-specific effects of ORM2 in AP pathogenesis and repair. Methods: We established cerulein-induced mouse model of AP using both wild-type and pancreas-specific ORM2 knockout mice to investigate ORM2's protective role. Primary acinar cells were used for Results: In AP models, we observed opposing expression patterns of ORM, with increased levels in the liver but decreased levels in the pancreas. Genetic deletion of pancreatic ORM2 significantly worsened AP severity, while exogenous ORM2 administration provided protection against pancreatic injury. Specifically, ORM2 upregulated SPINK1 while downregulating PRSS2, leading to reduced trypsin activation. Conclusions: ORM2 protects against AP by modulating the SPINK1-PRSS2 axis to prevent premature trypsin activation and alleviate acinar cell injury. Its tissue-specific regulation suggests therapeutic potential for AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.